Rivaroxaban Dosing Adjustment for Verapamil Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rivaroxaban dosing in patients concomitantly administered verapamil poses a risk of increased bleeding due to reduced clearance and increased exposure, as existing methods lack standardized monitoring and dosing adjustments for drug interactions.
Innovation Solution
Administering a reduced dose of rivaroxaban, ranging from 0% to 99.5% of the recommended dose, tailored to individual renal function and concomitant verapamil administration, to maintain optimal plasma concentrations and minimize adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the recommended dose of rivaroxaban is administered to patients concomitantly taking verapamil, then the anticoagulant effect is maintained, but the risk of bleeding increases due to reduced clearance and increased exposure
Solution Approach 1:
The patent adjusts the rivaroxaban dose parameter based on the presence of verapamil co-administration and renal function status. Specifically, it recommends reducing the rivaroxaban dose to 15 mg once daily (from the standard 20 mg) for patients with normal renal function taking verapamil, and further reducing to 7.5-15 mg once daily for patients with renal impairment. This parameter change resolves the contradiction by maintaining adequate anticoagulant effect while preventing excessive exposure and bleeding risk.
2Object-affected harmful factors
If the rivaroxaban dose is reduced to minimize bleeding risk, then the safety is improved, but the risk of thrombotic events increases due to insufficient anticoagulation
Solution Approach 1:
The patent implements a feedback-based dosing strategy that considers patient-specific factors (renal function status and verapamil co-administration) to determine the appropriate rivaroxaban dose. By monitoring these parameters and adjusting the dose accordingly (20 mg → 15 mg → 7.5-15 mg based on renal function), the system maintains the anticoagulant effect within the therapeutic window, preventing both bleeding and thrombotic events.
3Ease of operation
If standardized dosing guidelines are established for rivaroxaban-verapamil interactions, then the ease of operation is improved, but the complexity of dosing recommendations increases due to multiple patient subgroups
Solution Approach 1:
The patent segments the patient population into distinct subgroups based on renal function status (normal vs. impaired) and verapamil co-administration status. This segmentation creates clear, manageable dosing recommendations for each subgroup: 15 mg once daily for normal renal function with verapamil, and 7.5-15 mg once daily for renal impairment. This structured approach simplifies clinical decision-making while accounting for the complexity of different patient scenarios.
Data Source
AI summary
The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.